Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis.
Suguru YamadaT FujiiTomohisa YamamotoH TakamiI YoshiokaS YamakiF SonoharaK ShibuyaF MotoiS HiranoYoshiaki MurakamiH InoueM HayashiK MurotaniJ KitayamaH IshikawaY KoderaM SekimotoSohei SatoiPublished in: The British journal of surgery (2020)
Adding intraperitoneal paclitaxel had clinical efficacy with acceptable tolerability.